Talphera TLPH
NASDAQ TLPH
$1.08 +0.03 (+2.86%)
At close: Oct 23, 2026 · 4:00 PM EDT

Talphera (TLPH) Gains from Sales and Divestitures (2015)

Updated

Talphera's Gains from Sales and Divestitures was -$12,000 in FY2017.

Analysis

Talphera (TLPH) Gains from Sales and Divestitures (2015) Analysis & Trends

  • The FY2017 figure marks the highest annual Gains from Sales and Divestitures since FY2010.
  • Per Business Quant data, Gains from Sales and Divestitures in earlier years was -$573,000 in FY2015.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Talphera 81.57 Mn 64.49 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2015 -64,000.00
API Access

Talphera Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=TLPH&period=max&api_key=YOUR_API_KEY